The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)
Latest Information Update: 17 Sep 2025
At a glance
- Drugs Iparomlimab/tuvonralimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms Neo-IT
Most Recent Events
- 17 Sep 2025 New trial record